Brief: Cellares And Lyell To Evaluate Automated Manufacturing Of Lyell's Car T-Cell Therapy
11/09/2023 13:52
Sept 11 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* CELLARES AND LYELL TO EVALUATE AUTOMATED MANUFACTURING OF
LYELL'S CAR T-CELL THERAPY ON CELLARES' CELL SHUTTLE PLATFORM
Source text for Eikon: ID:nGNX72D3H6
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma